Piombino Dese, Italy-based Stevanato Group designed Vertiva with the ability to switch between basal and bolus injections. It has suitability for a wide range of subcutaneous therapies.
In March, Stevanato Group announced plans to bring this on-body device to market through a collaboration with Thermo Fisher Scientific. The companies plan to offer the platform as an integrated device and fill-and-finish solution.
The company designed Vertiva with a single-use pod featuring a pre-filled and pre-loaded 3mL ISO cartridge. It also comes with a multi-use controller for potential sustainability and affordability benefits. Both parts communicate through a patented, magnetically coupled drive mechanism.
Stevanato Group said its device can adapt to different delivery profiles and enable the administration of small-molecule drugs and biologics. The company has the design under development to cover a broad range of volumes up to 10mL.
More about the Stevanato Group Vertiva on-body drug delivery device
Vertiva’s pre-loaded cartridge, sealed into the pod during factory assembly, allows the patient to benefit from simplified treatment initiation. They can conduct administrations more comfortably at home while Vertiva’s connectivity options enable digital health applications. Upon treatment, the user can easily separate their pod and controller, Stevanato Group said. Plus, the reusable controller helps reduce the environmental impact of the system’s electronic components.
With its programmable micro-precision basal doses and full-content basal injections, Vertiva can cover a range of therapies. These include cardiovascular and metabolic disorders, as well as oncology, immunology and pain management applications. Stevanato Group designed it to accommodate different customizations, too, such as larger injection volumes, delivery duration and user interface.
“The Vertiva on-body delivery system supports pharma companies in increasing the accessibility of in-home care and administered treatment options, which can ultimately lead to an improved patient experience,” said Steven Kaufman, VP for drug delivery systems at Stevanato Group. “We are excited to be offering this device to the market, as it contributes to further strengthening our integrated capabilities in the drug delivery space. By utilizing a re-usable controller, we work towards greater sustainability and see cost benefits to our customers that use Vertiva™.”
